216 related articles for article (PubMed ID: 28223815)
1. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.
Yin L; Zhao C; Han J; Li Z; Zhen Y; Xiao R; Xu Z; Sun Y
Ther Clin Risk Manag; 2017; 13():117-130. PubMed ID: 28223815
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity.
Zhang W; Wang F; Hu X; Liang J; Liu B; Guan Q; Liu S
Oncol Lett; 2019 Jan; 17(1):815-822. PubMed ID: 30655834
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
4. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
[TBL] [Abstract][Full Text] [Related]
5. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.
Zhang W; Hu X; Liang J; Zhu Y; Zeng B; Feng L; Zhao C; Liu S; Liu B; Zhang K
Mol Ther Oncolytics; 2020 Mar; 16():158-171. PubMed ID: 32055679
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity.
Zhang W; Zeng B; Hu X; Zou L; Liang J; Song Y; Liu B; Liu S
Hum Gene Ther; 2021 Feb; 32(3-4):203-215. PubMed ID: 33176492
[TBL] [Abstract][Full Text] [Related]
8. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
[TBL] [Abstract][Full Text] [Related]
9. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.
Zhu Y; Hu X; Feng L; Yang Z; Zhou L; Duan X; Cheng S; Zhang W; Liu B; Zhang K
Mol Ther Oncolytics; 2019 Dec; 15():201-213. PubMed ID: 31788554
[TBL] [Abstract][Full Text] [Related]
11. [Replication and expression of oncolytic herpes simplex virus type Ⅱ in tumors].
Cai Q; Zhang S; Liu H; Liu B
Sheng Wu Gong Cheng Xue Bao; 2024 Feb; 40(2):585-595. PubMed ID: 38369843
[TBL] [Abstract][Full Text] [Related]
12. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.
Hu H; Zhang S; Cai L; Duan H; Li Y; Yang J; Wang Y; Liu B; Dong S; Fang Z; Liu B
Virol J; 2022 Apr; 19(1):74. PubMed ID: 35459242
[TBL] [Abstract][Full Text] [Related]
13. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
14. Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models.
Yang H; Peng T; Li J; Wang Y; Zhang W; Zhang P; Peng S; Du T; Li Y; Yan Q; Liu B
Gene Ther; 2016 May; 23(5):450-9. PubMed ID: 26871935
[TBL] [Abstract][Full Text] [Related]
15. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer.
Todryk S; McLean C; Ali S; Entwistle C; Boursnell M; Rees R; Vile R
Hum Gene Ther; 1999 Nov; 10(17):2757-68. PubMed ID: 10584922
[TBL] [Abstract][Full Text] [Related]
16. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
17. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
18. Intestinal Microbiota Modulates the Antitumor Effect of Oncolytic Virus Vaccines in Colorectal Cancer.
Chen X; Wang G; Qin L; Hu B; Li J
Dig Dis Sci; 2024 Apr; 69(4):1228-1241. PubMed ID: 38400885
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1/CD3 bispecific antibody.
Wang Y; Wang R; Hu H; Jin J; Cai L; Zhang S; Yi F; Li Y; Zheng Z; Zhou Q; Fang Z; Liu B
Int Immunopharmacol; 2023 Nov; 124(Pt B):110975. PubMed ID: 37757634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
